What to Expect From Mylan Earnings

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
What to Expect From Mylan Earnings

© courtesy of Mylan Specialty L.P.

Mylan N.V. (NASDAQ: MYL) is scheduled to report its third-quarter financial results after the markets close on Wednesday. The consensus estimates from Thomson Reuters are $1.46 in earnings per share (EPS) and $3.12 billion in revenue. In the same period of last year, Mylan posted EPS of $1.43 and $2.71 billion in revenue.

Within the past month, Mylan reached an agreement with the U.S. Department of Justice to pay $465 million to resolve questions about the classification of it EpiPen auto-injector products for purposes of the Medicaid drug rebate program.

At that time, the company has reduced its full fiscal 2016 adjusted earnings per share (EPS) guidance from a prior range of $4.85 to $5.15 to a new range of $4.70 to $4.90. Mylan attributed the majority of the change to “previously announced changes in EpiPen Auto-Injector access programs and the upcoming launch of the generic to EpiPen Auto-Injector.”

[nativounit]

Mylan also said the settlement terms “provide for resolution of all potential rebate liability claims by federal and state governments as to whether the product should have been classified as an innovator drug for [Centers for Medicaid and Medicare Services] CMS purposes and subject to a higher rebate formula.”

A few analysts weighed in on Mylan ahead of the earnings report:

  • Mizuho has a Buy rating with a $49 price target.
  • JPMorgan has a Buy rating with a $52 price target.
  • BTIG Research reiterated a Buy rating with a $55 price target.
  • RBC Capital Markets reiterated a Sector Perform rating with a $48 price target.
  • Leerink Swann has a Buy rating with a $45 price target.
  • Wells Fargo has a Hold rating with a $44 price target.
  • Argus has a Buy rating with a $55 price target.

Excluding Wednesday’s post-election move, Mylan has vastly underperformed the broad markets, with the stock down 31% year to date.

Shares of Mylan were trading up 5% at $39.07 on Wednesday, with a consensus analyst price target of $52.53 and a 52-week trading range of $33.60 to $55.51.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618